Image-guided therapy firm Brainlab has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Contrast Clearance Analysis software.
Designed to provide additional insight into post-treatment tumor characteristics, Contrast Clearance Analysis analyzes MR images to differentiate regions of efficient contrast clearance from regions with contrast accumulation in most cranial tumor patients, according to the vendor.
The software acquires two MRI scans -- one at five minutes after the injection of a standard contrast agent dose and another at least an hour later. It then subtracts the first series from the second to show the difference between contrast clearance and accumulation, Brainlab said.
